SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

After a strong earnings report, Intel's stock is trending, but not without volatility as the community debates whether government involvement and accounting practices are sustainable growth drivers. Some traders are targeting short positions, while others believe the pullback is a buying opportunity before a longer-term climb. Discussions also involve Intel's competition with TSMC and potential partnerships in the semiconductor sector.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending as investors assess its potential in the quantum computing and AI spaces following news of key partnerships and ahead of upcoming earnings. Community discussions revolve around IBM's valuation relative to pure-play quantum stocks, with some highlighting its established position and real-world applications versus the hype surrounding smaller companies. Recent analyst activity and overall market sentiment are also contributing to the stock's current buzz.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines is trending as community members discuss the potential impact of a Pentagon contract win and the involvement of Trump Jr. Some are also pointing to UMAC's existing investments in other drone companies, while others are speculating about the effect of a potential government shutdown on future contracts. The stock's price action, including a recent trading halt, has also fueled conversation.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as traders discuss its potential for a short squeeze, pointing to high borrow costs and a tightly held float. Community members are actively debating the mechanics of a potential squeeze, with some suggesting insiders may be strategically accumulating shares. Bearish sentiment remains, with some traders adding to short positions, while bulls anticipate a significant price increase.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a potential short squeeze fueled by recent news including insider buying and milestone payments from Merck. Community members are discussing the stock's low float and potential for significant upward movement.  However, some traders are wary of potential dilution.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is trending as investors discuss its potential for a turnaround, spurred by the golden cross pattern and upcoming earnings. Community members are pointing to the large institutional ownership and catalysts such as government healthcare commitments and AI integration as reasons for potential upside. Some traders are also highlighting potential short squeeze opportunities.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Slap is trending due to community enthusiasm and its association with pro MMA fighter Karolina Arm, who represents Team SLAP. The coin has seen a price jump, and discussions revolve around its strong community and potential for mainstream adoption. Bullish sentiment is high, with community members emphasizing its unique meme-driven approach within the crypto space.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

DECK is seeing active discussion around its recent performance and future prospects, with community members debating whether it's undervalued or facing headwinds. The stock's movement is attributed to factors beyond earnings, including concerns about guidance and potential tariff impacts. Bulls are pointing to the company's strong cash flow and potential buybacks.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential as an AI infrastructure play, particularly following a reported partnership with Palantir. Community talking points include the company's fiber optic network and data center connectivity, with some seeing a possible short squeeze. Despite positive sentiment, concerns persist around debt and revenue growth.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as the company prepares to launch DraftKings Predictions, expanding into prediction markets through the acquisition of Railbird and regulated event contracts. The community is discussing the strategic implications of this move, including potential competition with existing platforms and the impact on state regulations, with many bullish on the company's long-term prospects amid a recent price drop.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio logged its fourth straight day of gains on Tuesday, climbing to its highest level in nearly a month as shares broke above the 200-day moving average amid optimism from Anktiva trial data showing survival benefits in lung cancer patients.Technical SetupImmunityBio Investor and former UBS analyst David Din&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DavidDin/status/1967895088643895767">said in a post on X</a> that the stock has finally broken out of a long slump dating back to April 2024, now showing a pattern of “higher highs and higher lows.”&nbsp;<img src="https://news.stocktwits-cdn.com/longterm_downward_trend_jpg_bc73477cdd.webp" alt="longterm downward trend.jpg">He pointed to several bullish indicators: a&nbsp;moving average convergence divergence (MACD) crossover (a signal that momentum is shifting upward) and a divergence in relative strength index (showing buying strength building even while the stock had been falling).<img src="https://news.stocktwits-cdn.com/moving_averages_jpg_47d36e8b5a.webp" alt="moving averages.jpg">He also pointed to a positive signal from the Ichimoku Cloud indicator, which provides both forward- and backward-looking views of market trends. For IBRX, the short-term conversion line (blue) has crossed above the longer-term baseline (red), a move that could signal a bullish shift in momentum.<img src="https://news.stocktwits-cdn.com/ichimoku_cloud_jpg_af4d9c4a78.webp" alt="ichimoku cloud.jpg">Din described the move above the 200-day moving average as “huge,” noting the stock had tested this level before but pulled back, and could now make another attempt to push higher.&nbsp;He marked $3.04 as the next Fibonacci level, comparing the setup to past surges he called “God Candles,” where the stock jumped 20%–27% in a single day and cleared multiple technical barriers.He added that Bollinger Bands, which measure volatility, are starting to widen, similar to October 2024 when a sudden spike helped define the stock’s long-term downtrend. With that trendline now broken, Din said there is no major technical ceiling left to stop another strong move.Din also flagged a gap on the chart at $4.50, predicting it would be filled, and noted that shorter-term moving averages are lining up in a bullish fashion: the 21-day average is nearing a crossover of the 50-day, the 50-day is close to crossing the 125-day, and the 200-day is now within reach.Lung Cancer StudyThe stock’s momentum comes alongside clinical data presented at the IASLC 2025 World Conference on Lung Cancer.&nbsp;ImmunityBio reported that its experimental drug, Anktiva, reversed lymphopenia in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer. Patients showed absolute lymphocyte counts above 1,500 cells/μL, achieving a median overall survival of 21.1 months.On Stocktwits, retail sentiment for ImmunityBio was ‘bullish’ amid ‘high’ message volume, with traders upbeat on strong charts, rising volumes, and fresh buying interest.On Stocktwits, one user noted that ImmunityBio shares were trading around $2.90, describing it as a key resistance level, and said the move higher came with strong momentum, as both price and volume continued to exceed recent averages.<stembedurl>https://stocktwits.com/Bc3345/message/628904525</stembedurl>Another user mentioned they had accumulated several thousand shares in anticipation of a breakout. A third said the three-month chart looked “extremely bullish,” while a fourth remarked that they liked the setup and had taken a large position in the stock.<stembedurl>https://stocktwits.com/Stayinvest/message/628914954</stembedurl><stembedurl>https://stocktwits.com/Thorbig/message/628917335</stembedurl><stembedurl>https://stocktwits.com/OliveGardenCPA/message/628901589</stembedurl><a href="https://stocktwits.com/symbol/IBRX">ImmunityBio’s stock</a> has risen 9.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals

The stock’s recent momentum has been fueled by fresh optimism around trial data for its cancer drug Anktiva, which showed survival benefits in resistant lung cancer patients.

Equity

The last few months have seen a resurgence in social media-driven stock trades,&nbsp;resulting in a crop of new meme stocks,&nbsp;including Opendoor, GoPro, Kohl's, and Krispy Kreme.Now, JPMorgan has identified a few more names to keep a tab on. "We are flagging a few stocks that are heavily mentioned on Social Media and have high Retail buying as well as high Hedge fund Shorting," the investment research said in a note to clients, according to<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/09/11/four-meme-stocks-with-high-social-activity-and-hedge-funds-shorts-according-to-jpmorgan.html">&nbsp;CNBC</a>. "These stocks may experience unexpected flows in case of increased activity."Here are JPMorgan's picks and brief notes on their recent moves:&nbsp;Hims &amp; Hers HealthThe weight loss and health management company's stock has fluctuated significantly between peaks and troughs. Earlier this year, the company entered into a partnership with Novo Nordisk to distribute the latter's Wegovy, a popular GLP-1 weight loss drug. However, a few months later, the Danish pharmaceutical major canceled the partnership, citing Hims &amp; Hers' failure to prevent "knockoff" compounded versions of Wegovy and for engaging in deceptive marketing.U.S. regulators have rapped Hims &amp; Hers for its drug marketing practices, and investors are closely watching the company's moves.Year-to-date gain: 110%Short interest: 31.1%Stocktwits sentiment:&nbsp;Bullish&nbsp;ImmunityBioThe cancer-focused biotech firm has seen interest, driven by clinical-stage Anktiva,&nbsp;designed to boost the immune system's tumor-fighting response, and&nbsp;immunotherapies that target and kill cancer cells. Although the company's stock has mostly&nbsp;traded rangebound this year, shares have jumped double-digit percentages on several occasions in reaction to positive trial data.Year-to-date gain: 0.4%Short interest: 8%Stocktwits sentiment:&nbsp;Bullish&nbsp;Rocket CompaniesThe mortgage and house-owning services firm has seen its stock climb steadily this year, with a recent bump accompanying renewed expectations of a potential lowering of interest rates. The stock hit a 52-week high earlier this week.In March, the Rocket Companies announced a massive $9.4-billion all-stock acquisition of competitor Mr. Cooper Group, lifting investor confidence. The company's business is closely tied to the housing market, which is experiencing a modest rebound.Year-to-date gain: 97%Short interest: 5.3%Stocktwits sentiment:&nbsp;Bullish&nbsp;SoundHound AIAfter a whopping 836% rise in 2024, SoundHound shares have traded comparatively sombrely this year. That said, several analysts have recently begun covering the company, impressed by its voice-based AI technology.In July, the company reported a 217% rise in its second-quarter revenue and increased its sales guidance for the whole year.Year-to-date loss: 29%Short interest: 28.7%Stocktwits sentiment:&nbsp;Bullish&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/rent-the-runway-stocks-plummets-27-after-hours-on-mounting-losses-surging-costs-retail-traders-still-bullish/chw8hPeRdwL">&nbsp;Rent The Runway Stocks Plummets 27% After-Hours On Mounting Losses, Surging Costs — Retail Traders Still Bullish</a>

Traders work on the floor of the New York Stock Exchange during morning trading on August 26, 2025, in New York City. 

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts

Meme mania has resurged in the past few months.

ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

ImmunityBio (IBRX) delivered earnings and revenue surprises of 0.00% and +0.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

ImmunityBio's short interest hit a two-month high of 54% this week, representing an increase from under 30% since early March, despite solid&nbsp;first-quarter operational and financial outcomes.&nbsp;The days-to-cover metric decreased from 14.9 to 14.2 as trading volume increased throughout the last two weeks, according to Ortex data, compiled by The Fly.Shares of the pharma firm closed at $2.84, up 6.37% on Friday, before slipping 1.06% to $2.81 in after-hours trading.The company's Q1 2025 net loss was $129.6 million, a minor improvement from the $134.1 million loss&nbsp;a year earlier.ImmunityBio generated net product revenue of about $16.5 million in Q1 ending March 31, 2025, representing a 129% increase from $7.2 million in Q4 2024.&nbsp;The permanent J-code approval for Anktiva helped providers streamline billing and reimbursement, which led to growth.&nbsp;Anktiva is ImmunityBio’s immunotherapy for non-muscle invasive bladder cancer (NMIBC) that helps address the shortage of BCG (Bacillus Calmette-Guérin), a vaccine used to stimulate the immune system against bladder cancer.&nbsp;Unit sales for Anktiva rose by 150% in Q4 2024, while March sales showed a 69% increase over February due to nearly 200 urology practices enrolling in the rBCG Expanded Access Program to overcome the national BCG shortage.CEO Richard Adcock said that Anktiva's revenue growth remained steady because urologists across rural areas began treating NMIBC carcinoma in situ patients with this drug when other treatment options were scarce.&nbsp;ImmunityBio presented positive long-term clinical data from the QUILT 3.032 study concerning Anktiva benefits for non-muscle invasive bladder cancer patients at the American Urological Association meeting in 2025.On Stocktwits, retail sentiment&nbsp;for IBRX was ‘extremely bullish’ amid ‘high’ message volume.One user expressed optimism about ImmunityBio’s stock potentially reaching and closing at $3 the following day, showing a bullish outlook.&nbsp;<stembedurl>https://stocktwits.com/Gee8tch3/message/615048708</stembedurl>Another user predicted that the stock could rise significantly higher in the coming month.<stembedurl>https://stocktwits.com/BullHustler_/message/615041058</stembedurl>The stock has risen 10.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside

Retail traders showed bullish sentiment following strong Q1 revenue growth and positive clinical data for its bladder cancer drug, despite a 54% jump in short interest.

ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

Shares of ImmunityBio, Inc. (IBRX) tumbled 18% on Monday afternoon after the company announced that it received a Refuse to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its bladder cancer treatment application.The FDA issues refuse-to-file letters if it identifies deficiencies in a company’s application for drug approval.ImmunityBio <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250505409104/en/ImmunityBio-Requests-an-Urgent-Meeting-With-FDA-to-Address-the-Change-in-the-Agencys-Unambiguous-Guidance-on-Jan-2025-to-Submit-a-sBLA-for-NMIBC-BCG-Unresponsive-Papillary-Disease-Following-an-Inconsistent-Refusal-to-File-Letter-on-May-2-2025">received</a> an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle invasive bladder cancer (NMIBC).ImmunityBio said that the application was submitted in March after all key decision makers at the FDA encouraged it to submit the application “as soon as possible” at an in-person meeting in January.“At this meeting, all key decision makers were specifically asked and unanimously confirmed that ImmunityBio should submit the sBLA as soon as possible based on the data in the single-arm trial,” the company said. &nbsp;The company also said that it has requested an urgent meeting with the FDA to resolve the inconsistencies between the directives it received in January and the letter it recently received, adding that it was “shocked” by the FDA's “inconsistent response.”The company also highlighted that the FDA approved the use of ANKTIVA plus BCG last year for another scenario of NMIBC based on the same trial data that it referred to in the recently submitted application.On Stocktwits, retail sentiment around ImmunityBio jumped from ‘bearish’ to ‘bullish’ over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:629/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_05_at_1_56_52_PM_png_129dd641b3.webp" alt="IBRX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 5, 2025 | Source: Stocktwits" width="629" height="68"><figcaption>IBRX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 5, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> is down by 19% this year and over 73% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apple-escalates-epic-games-fight-with-appeal-stock-falls-after-price-target-cut/chid4BRRb1d">Apple Escalates Epic Games Fight With Appeal – Stock Falls After Price Target Cut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive

ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle invasive bladder cancer (NMIBC).

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after-hours trading.The rally followed the company’s announcement that the U.S. Food and Drug Administration&nbsp;(FDA) has authorized an expanded access program. This program will provide patients in the U.S. with a critical alternative source of BCG, a standard-of-care treatment for bladder cancer.ImmunityBio said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.&nbsp;A recent Sermo survey of 100 U.S. urologists found that 57% could not treat patients over the past year due to a lack of access to TICE BCG.&nbsp;The Serum Institute of India, the world’s largest vaccine manufacturer by volume, developed the alternative BCG source.In European clinical trials for bladder cancer, ImmunityBio said its recombinant BCG vaccine demonstrated strong immunogenicity with CD8+ and CD4+ T cell stimulation and improved safety compared to earlier BCG strains.<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IBRX_sentiment_and_message_volume_Feb_19_0a49f7ee60.png" alt="IBRX sentiment and message volume Feb 19.png" width="1316" height="316"><figcaption>IBRX sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for ImmunityBio turned even more bullish, with message volume surging by 450% by the end of Wednesday.&nbsp;Retail traders expressed enthusiasm, with one user calling the news “as good as it can get other than a bid” and another speculating that ImmunityBio’s combination therapy with Anktiva could become the new standard of care, replacing Merck’s BCG.<stembedurl>https://stocktwits.com/KNZtime/message/604937174</stembedurl><stembedurl>https://stocktwits.com/Fishbanger51/message/604931186</stembedurl>Shares of ImmunityBio have gained more than 50% so far this year, though short interest, according to Koyfin, climbed from 6.4% at the start of 2025 to 7.7% by the end of last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Light micrograph of a section through a transitional cell carcinoma (TCC, cancer) of the bladder wall. | Image source: Getty Images

ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies

The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE BCG Shortage

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital...

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunity therapy company, today announced the Medicines and Healthcare products Regulatory Agency (MHRA) has validated and accepted the marketing...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IBRX News

IBRXImmunityBio Inc